## **Supplemental Material**

# Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease

W Herrington<sup>1</sup>\* MD, N Staplin<sup>1</sup>\* PhD, PK Judge<sup>1,2</sup> MBChB, M Mafham<sup>1</sup> MD, J Emberson<sup>1,2</sup> PhD, R Haynes<sup>1,2</sup> DM, DC Wheeler<sup>3</sup> FRCP, R Walker<sup>4</sup> FRACP, C Tomson<sup>5</sup> DM, L Agodoa<sup>6</sup> FACP, A Wiecek<sup>7</sup> FRCP, S Lewington<sup>1,2</sup> DPhil, CA Reith<sup>1</sup> FRCP, MJ Landray<sup>1</sup> FRCP and C Baigent<sup>1,2</sup> FRCP on behalf of the SHARP Collaborative Group. \*Joint contribution

- 1. Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU),
- Nuffield Department of Population Health (NDPH), University of Oxford, UK
- 2. Medical Research Council Population Health Research Unit (MRC PHRU),
- NDPH, University of Oxford, UK
- 3. Centre for Nephrology, University College London, London, UK
- 4. Dunedin School of Medicine, University of Otago, Otago, New Zealand
- 5. Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK
- 6. National Institute of Diabetes and Digestive and Kidney Diseases,

National Institutes of Health, Bethesda, MD, USA

7. Department of Nephrology, Transplantation and Internal Medicine,

Medical University of Silesia, Katowice, Poland

Correspondence to: Prof. Colin Baigent

MRC-PHRU, NDPH, Richard Doll Building, Old Road Campus,

Roosevelt Drive, Oxford OX3 7LF, UK

Email: colin.baigent@ndph.ox.ac.uk

Phone: +44 1865 743743; Fax: +44 1865 743985

# **SHARP Steering Committee membership**

Colin Baigent, Martin J Landray, Christina Reith, Jonathan Emberson, David C Wheeler, Charles Tomson, Christoph Wanner, Vera Krane, Alan Cass, Jonathan Craig, Bruce Neal, Lixin Jiang, Lai Seong Hooi, Adeera Levin, Lawrence Agodoa, Mike Gaziano, Bertram Kasiske, Robert Walker, Ziad A Massy, Bo Feldt-Rasmussen, Udom Krairittichai, Vuddidhej Ophascharoensuk, Bengt Fellström, Hallvard Holdaas, Vladimir Tesar, Andrzej Wiecek, Diederick Grobbee, Dick de Zeeuw, Carola Grönhagen-Riska, Tanaji Dasgupta, David Lewis, William Herrington, Marion Mafham, William Majoni, Karl Wallendszus, Richard Grimm, Terje Pedersen, Jonathan Tobert, Jane Armitage, Alex Baxter, Christopher Bray, Yiping Chen, Zhengming Chen, Michael Hill, Carol Knott, Sarah Parish, David Simpson, Peter Sleight, Alan Young, Rory Collins.

### **Detailed Statistical Methods: Estimation of "Usual" Blood Pressure**

To ensure natural blood pressure variation and any measurement error was accounted for, a standard correction for such regression-dilution bias was made. (Supplemental Figure 2). Each individual's usual systolic blood pressure, S, was estimated using linear regression models with blood pressure at the study midpoint (2.5 years) as the outcome and their baseline value, s, as the explanatory variable. It was found that there was a quadratic relationship between baseline and follow-up blood pressure, so usual systolic blood pressure was estimated using the formula:

$$S=136.1 + 0.316(s - 138.9) - 0.001(s - 138.9)^2$$
.

Similarly, each individual's usual diastolic blood pressure, D, was calculated from their baseline value, d, using the formula:

$$D=77.1 + 0.396(d - 79.1) - 0.0018(d - 79.1)^2$$
.

A similar method of estimation of usual blood pressure has been used previously in the analyses of the influence of blood pressure on vascular disease risk performed by the Prospective Studies Collaboration.<sup>3</sup>

The following hazard ratios demonstrate how the use of a single blood pressure measurement or the average of 3 readings over 6 months would underestimate the relevance of SBP to vascular risk (among those who reported no previous history of cardiovascular disease and a baseline troponin-I ≤0.01ng/mL) compared to using the usual SBP described above.

	Hazard ratio (95% CI) per 10 mmHg higher SBP
"Usual" SBP	1.29 (1.12-1.48)*
Average SBP of 3 readings over 6 months	1.11 (1.05-1.16)
Single baseline measure of SBP	1.08 (1.04-1.13)

SBP = systolic blood pressure. \*The hazard ratio quoted here for "usual" SBP differs to that quoted in Figure 3 as these analyses exclude participants with missing values of SBP at 2 or 6 months.

#### **Statistical References**

- 1. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, Peto R. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. *Am J Epidemiol*. 1999;150:341-353.
- 2. Carroll RJ, Ruppert D, Stefanski LA, Crainiceanu CM *Measurement error in nonlinear models: A modern perspective.* Boca Raton: CRC Press.; 2006.
- 3. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet*, 2002; 360:1903-1913.

Table S1: Baseline characteristics and laboratory measurements subdivided by self-reported history of prior cardiovascular disease and baseline troponin-I concentration

Self-reported history of previous cardiovascular disease and baseline troponin-I concentration No CVD Characteristic/measurement Tnl≤0.01 (n=4070) Tnl>0.01 (n=3208) CVD (n=1388) **Blood pressure** Baseline systolic (mmHg) 136 (20) 142 (23) 141 (23) Baseline diastolic (mmHg) 80 (12) 79 (13) 76 (13) Usual systolic (mmHg) 135 (6) 136 (7) 136 (7) Usual diastolic (mmHg) 77 (5) 77 (5) 76 (5) Any antihypertensive medication 3405 (84%) 2722 (85%) 1194 (86%) **Demographics** Age at randomization (years) 59 (11) 64 (12) 67 (11) 2338 (57%) 2193 (68%) 910 (66%) Men Ethnicity 2985 (73%) White 2222 (69%) 1033 (74%) Black 73 (2%) 104 (3%) 41 (3%) Asian 908 (22%) 786 (25%) 272 (20%) Other 104 (3%) 96 (3%) 42 (3%) Education University 569 (14%) 307 (10%) 120 (9%) Secondary school 1377 (34%) 1016 (32%) 435 (31%) Vocational qualifications 891 (22%) 768 (24%) 366 (26%) Primary school or no formal education 651 (16%) 647 (20%) 287 (21%) Not specified 582 (14%) 470 (15%) 180 (13%) Current smoker 560 (14%) 387 (12%) 207 (15%) Prior disease Self-reported history of cardiovascular disease 0 (0%) 0 (0%) 1388 (100%) Troponin-I (ng/mL) ≤0.01 4070 (100%) 0 (0%) 527 (38%) 551 (40%) >0.01 to ≤0.03 0 (0%) 2502 (78%) >0.03 to ≤0.1 0 (0%) 591 (18%) 186 (13%) >0.1 0 (0%) 40 (3%) 115 (4%) Diabetes 621 (15%) 859 (27%) 506 (36%) Renal status 3187 (78%) 1731 (54%) 926 (67%) Not on dialysis On dialysis 878 (22%) 1474 (46%) 460 (33%) Measurements CKD-EPI-estimated GFR (mL/min/1.73m²)\* Mean (SD) 26.6 (13.3) 23.2 (12.0) 25.0 (13.0) ≥60 49 (1%) 20 (1%) 13 (1%) ≥30 to <60 1127 (28%) 426 (13%) 263 (19%) ≥15 to <30 1375 (34%) 790 (25%) 411 (30%) <15 639 (16%) 498 (16%) 211 (15%) Urinary albumin:creatinine ratio (mg/g)\* Median (IQR) 175 (37-645) 253 (60-896) 224 (49-979) <30 648 (16%) 267 (8%) 153 (11%) ≥30 to ≤300 596 (19%) 293 (21%) 1159 (28%) >300 1152 (28%) 752 (23%) 363 (26%) Body-mass index (kg/m²) 27.0 (5.3) 27.0 (5.7) 27.4 (5.6) **Treatment allocation** 

Mean (SD) or n (%) shown. GFR=glomerular filtration rate. CVD = self-reported history of cardiovascular disease. Tnl=troponin-I. \*For participants not on dialysis. Missing data as described in Table.

2014 (49%)

1630 (51%)

Randomized to simvastatin plus ezetimibe

Table S2: Additional baseline characteristics and laboratory measurements by tertiles of baseline blood pressure

	Sy	Systolic blood pressure (SBP)				Diastolic blood pressure (DBP)			
Characteristic/measurement	Bottom third (n=3123)	Middle third (n=3015)	Top third (n=3119)	P value*	Bottom third (n=3084)	Middle third (n=3143)	Top third (n=3019)	P value†	
Other demographics									
Ethnicity				<0.0001				0.0016	
White	74%	74%	67%		74%	72%	69%		
Black	3%	2%	3%		3%	3%	3%		
Asian	20%	21%	26%		21%	23%	24%		
Other	3%	3%	3%		3%	3%	4%		
Education				< 0.0001				0.21	
University	13%	12%	10%		11%	12%	12%		
Secondary school	32%	34%	31%		32%	34%	33%		
Vocational qualifications	22%	23%	24%		24%	22%	23%		
Primary school or no formal education	17%	17%	21%		19%	18%	19%		
Not specified	15%	14%	14%		15%	14%	14%		
Current smoker	12%	13%	14%	0.07	13%	12%	14%	0.03	
Medications									
Number of antihypertensive medications				< 0.0001				0.01	
None	19%	15%	13%		17%	17%	14%		
One	26%	23%	23%		23%	25%	24%		
Two	24%	26%	25%		23%	25%	28%		
Three or more	30%	36%	38%		38%	33%	34%		
Type of antihypertensive medication									
ACE inhibitor or ARB	53%	55%	55%	0.12	54%	54%	55%	0.42	
Beta blocker	36%	38%	39%	0.03	38%	36%	39%	0.03	
Calcium channel blocker	32%	43%	48%	< 0.0001	40%	41%	43%	0.09	
Diuretic	41%	41%	42%	0.50	45%	40%	39%	<0.0001	
Other co-medication									
Antiplatelet therapy	23%	22%	23%	0.88	27%	21%	19%	<0.0001	
Oral anticoagulant therapy	4%	3%	3%	0.0021	4%	3%	3%	0.03	
Erythropoiesis stimulating agent	26%	26%	29%	0.01	31%	26%	25%	<0.0001	
Sevelamer	9%	7%	8%	0.17	10%	7%	7%	<0.0001	

Table S2: Additional baseline characteristics and laboratory measurements by tertiles of baseline blood pressure

Systolic blood pressure (SBP)				Diastolic blood pressure (DBP)				
Characteristic/measurement	Bottom third (n=3123)	Middle third (n=3015)	Top third (n=3119)	P value*	Bottom third (n=3084)	Middle third (n=3143)	Top third (n=3019)	P value†
Other measurements								
Body-mass index (kg/m²)	26.8 (5.4)	27.0 (5.4)	27.4 (5.4)	0.0005	27.1 (5.5)	27.2 (5.4)	27.0 (5.5)	0.44
Total cholesterol (mmol/L)	4.83 (1.15)	4.91 (1.15)	4.91 (1.16)	0.01	4.75 (1.17)	4.89 (1.14)	5.02 (1.16)	<0.0001
LDL cholesterol (mmol/L)	2.74 (0.86)	2.80 (0.86)	2.78 (0.86)	0.02	2.68 (0.87)	2.78 (0.85)	2.86 (0.87)	< 0.0001
HDL cholesterol (mmol/L)	1.11 (0.33)	1.12 (0.33)	1.13 (0.33)	0.09	1.08 (0.33)	1.12 (0.33)	1.15 (0.33)	< 0.0001
Triglycerides (mmol/L)	2.31 (1.73)	2.34 (1.72)	2.32 (1.73)	0.81	2.38 (1.75)	2.28 (1.72)	2.31 (1.75)	0.07
Phosphate (mmol/L)	1.26 (0.44)	1.27 (0.44)	1.30 (0.44)	0.0008	1.30 (0.44)	1.26 (0.44)	1.27 (0.44)	0.0015
Hemoglobin (g/dL)	12.28 (1.66)	12.17 (1.65)	12.05 (1.64)	< 0.0001	11.90 (1.66)	12.24 (1.63)	12.37 (1.67)	< 0.0001
Albumin (g/L)	40.1 (3.7)	40.2 (3.7)	40.0 (3.7)	0.04	39.9 (3.8)	40.2 (3.7)	40.1 (3.8)	0.0028
C-reactive protein (mg/L) [geometric mean (approximate SE)]	3.1 (0.1)	2.9 (0.1)	3.1 (0.1)	0.09	3.3 (0.1)	2.9 (0.1)	3.0 (0.1)	0.0004
Treatment allocation								
Randomized to simvastatin plus ezetimibe	50%	51%	50%	0.52	50%	50%	50%	0.91

Mean (SD) or % shown, all characteristics adjusted for age, sex and ethnicity, with the exception of ethnicity. ACE=angiotensin-converting enzyme. ARB=angiotensin-II receptor blocker. LDL=low-density lipoprotein. HDL=high-density lipoprotein. \*P value for test of heterogeneity between SBP categories. †P value for test of heterogeneity between DBP categories.

Table S3: Guideline recommendations for management of blood pressure in chronic kidney disease


Guideline	Blood pressure target, mmHg	Target population and recommendation
Kidney Disease Improving Global Outcomes (KDIGO, 2012) <sup>1</sup>	≤140/90 ≤130/80	CKD or diabetes without microalbuminuria CKD or diabetes with micro or macroalbuminuria
Eighth Joint National Committee (JNC-8, 2014) <sup>2</sup>	<140/90 <150/90	18-69 years and eGFR or mGFR <60 mL/min/1.73m <sup>2</sup> with albuminuria <sup>§</sup> eGFR <60 mL/min/1.73m <sup>2</sup> and ≥70 years <sup>∥</sup> , or CKD without albuminuria
European Society of Hypertension (ESH) and the European Society of Cardiology (ESH-ESC, 2013) <sup>3</sup>	<140/90 <130/90	CKD <sup>¶</sup> Overt proteinuria <sup>#</sup>
National Institute for Health and Clinical Excellence (NICE, 2014) <sup>4</sup>	<140/90 <130/80	Non-diabetic CKD <sup>*</sup> without albuminuria <sup>**</sup> CKD <sup>*</sup> with albuminuria <sup>††</sup> CKD <sup>*</sup> with diabetes
American College of Cardiology Foundation and the American Heart Association (ACCF/AHA, 2011) <sup>5</sup>	<130/80	CKD <sup>‡‡</sup> in elderly patients with hypertension
Canadian hypertension education program (CHEP, 2015) <sup>6</sup>	<140/90 <130/80	Non-diabetic CKD <sup>‡‡</sup> Diabetic CKD <sup>‡‡</sup>

CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; mGFR = measured glomerular filtration rate. CKD defined using the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NFK KDOQI) definition as; either kidney damage (defined as pathological abnormalities or markers of damage, including abnormalities in blood or urine tests or imaging studies) or GFR <60 mL/min/1.73m² for ≥3 months; <sup>†</sup> Microalbuminuria defined as urine albumin excretion ≥30-300 mg/d; <sup>‡</sup> Macroalbuminuria defined as urine albumin excretion >300 mg/d; <sup>§</sup> Albuminuria defined as >30 mg/g at any age and at any level of GFR; <sup>∥</sup> If ≥70 years, treatment should be individualised, taking into consideration factors such as frailty, comorbidities and albuminuria; <sup>¶</sup> CKD includes those with reduced renal function and/or the detection of elevated urinary excretion of albumin, staged according to eGFR; <sup>#</sup> Overt proteinuria defined as >300 mg/d; <sup>™</sup> Albuminuria defined as albumin:creatinine ratio ≥30 mg/mmol; <sup>††</sup> Albuminuria defined as albumin:creatinine ratio ≥70 mg/mmol; <sup>‡‡</sup> CKD defined as eGFR <60 mL/min/1.73 m²

#### References for Table S3

- 1. Kidney Disease Improving Global Outcomes (KDIGO). KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2012;2(5).
- 2. James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520.
- 3. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J hypertens*. 2013;31:1281-1357.
- 4. National Institute for Health and Clinical Excellence (NICE): Guidance. Chronic kidney disease (partial update): Early identification and management of chronic kidney disease in adults in primary and secondary care. Clinical Guideline 182. London: National Institute for Health and Care Excellence (UK) Copyright (c) National Clinical Guideline Centre. 2014. https://www.nice.org.uk/guidance/cg182 (accessed 20th July 2015).
- 5. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. *J Am Coll Cardiol*. 2011;57:2037-2114.
- 6. Daskalopoulou SS, Rabi DM, Zarnke KB, et al. The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. *Canadian J Cardiol.* 2015;31:549-568.

Figure S1: Causal diagram showing the assumed associations between baseline blood pressure, outcomes and other characteristics




RRT=renal replacement therapy. \*Age, sex, ethnicity, country, education, smoking status at screening, previous cardiovascular disease, previous diabetes mellitus and body mass index.

Analyses were adjusted for the confounders enclosed by boxes in the causal diagram. No adjustment was made for antihypertensive use as it was assumed that any effect on outcomes was mediated through its effect on blood pressure.


†The *a priori* assumption was that urinary albumin excretion lies on the causal pathway between blood pressure and vascular outcomes and is not a confounder, however sensitivity analyses including adjustment for urinary albumin excretion were conducted.

Figure S2: Mean blood pressure over follow-up in categories defined by quintiles of baseline measurement




SBP=systolic blood pressure. DBP=diastolic blood pressure. Excludes 4161 participants with missing BP values at any of the follow–up visits.

Figure S3: Association between systolic blood pressure, diastolic blood pressure and pulse pressure and cardiovascular events, subdivided by evidence of previous cardiovascular disease, for those less than 62 years old and 62 years or over



SBP=systolic blood pressure. DBP=diastolic blood pressure. PP=pulse pressure. CVD=self-reported history of cardiovascular disease. Tnl=troponin–I (ng/mL). HR=hazard ratio. For each plot, categories of blood pressure contain similar numbers of events. Hazard ratios adjusted for age, sex, ethnicity, country, education, smoking status, previous diabetes mellitus, renal replacement therapy status, eGFR, body-mass index and treatment allocation are quoted (above squares) with numbers of events (below). Exclusions as per Table. \*Hazard ratios per 10 mmHg higher usual SBP/PP are presented for associations where there is no evidence of deviation from a log-linear relationship.

Figure S4: Association between (A) systolic blood pressure, (C) diastolic blood pressure and (E) pulse pressure and non-vascular mortality overall, and association between (B) systolic blood pressure, (E) diastolic blood pressure and (F) pulse pressure and non-vascular mortality subdivided by evidence of previous cardiovascular disease



SBP=systolic blood pressure. DBP=diastolic blood pressure. PP=pulse pressure. HR=hazard ratio. CVD=self-reported history of cardiovascular disease. Tnl=troponin–I (ng/mL). For each plot, categories of blood pressure contain similar numbers of events. Hazard ratios adjusted for age, sex, ethnicity, country, education, smoking status, previous cardiovascular disease (panels A, C and E only), previous diabetes mellitus, renal replacement therapy status, eGFR, body–mass index and treatment allocation are quoted (above squares) with numbers of events (below). Exclusions as per Table. \*Hazard ratios per 10 mmHg higher usual SBP/PP and †hazard ratios per 5 mmHg higher usual DBP are presented for associations where there is no evidence of deviation from a log–linear relationship.